# Degarelix (Firmagon)

> GnRH antagonist providing immediate testosterone suppression in prostate cancer.

Source: https://peptides.cafe/peptide/degarelix
Category: GnRH Antagonist · Hormonal
Tag: FDA-Approved · Oncology

## Mechanism
Synthetic decapeptide GnRH receptor antagonist. Blocks GnRH receptors directly, producing rapid suppression of LH, FSH, and testosterone without the initial flare seen with agonists.

## Research areas
- Advanced prostate cancer

## Common research protocols
- Loading + maintenance: 240 mg SC loading, then 80 mg SC monthly.

## Study summaries
- "Degarelix vs leuprolide CS21 trial" — BJU International (2008): Faster testosterone suppression and no testosterone surge vs leuprolide.

## Considerations
- FDA-approved.
- Injection-site reactions common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.